Q3 25 EPS
$4.80
BEAT +4.87%
Est. $4.58
Q3 25 Revenue
$3.08B
BEAT +0.56%
Est. $3.06B
Did VRTX Beat Earnings? Q3 2025 Results
Vertex Pharmaceuticals delivered a solid beat on both the top and bottom lines in Q3 2025, with non-GAAP EPS of $4.80 clearing the $4.58 consensus by 4.87% and revenue of $3.08 billion edging past estimates by 0.56%, representing 11% growth year over… Read more Vertex Pharmaceuticals delivered a solid beat on both the top and bottom lines in Q3 2025, with non-GAAP EPS of $4.80 clearing the $4.58 consensus by 4.87% and revenue of $3.08 billion edging past estimates by 0.56%, representing 11% growth year over year. The quarter's strength was anchored by the company's dominant cystic fibrosis franchise, with TRIKAFTA/KAFTRIO contributing $2.65 billion alone, while newer launches added meaningful momentum: ALYFTREK generated $247 million in its first year on market, JOURNAVX added $19.60 million following its March debut, and CASGEVY contributed $16.90 million as cell therapy uptake continues to build. Despite the headline beat, shares came under pressure as investors weighed the pace of pipeline diversification. Looking ahead, Vertex narrowed its full-year 2025 revenue guidance to $11.90 billion to $12.00 billion and lowered its non-GAAP effective tax rate outlook to 17%-18%, while signaling increased investment in its povetacicept kidney disease program and JOURNAVX commercial expansion.
Key Takeaways
- • Continued strong CF patient demand including ALYFTREK uptake
- • Favorable net pricing in CF versus prior year in the U.S.
- • Early contributions from CASGEVY and JOURNAVX launches
- • Solid international performance across multiple geographies
VRTX YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
VRTX Revenue by Segment
With YoY comparisons, source: SEC Filings
VRTX Revenue by Geography
With YoY comparisons, source: SEC Filings
“Vertex delivered strong results across the board in the third quarter, extending our leadership in CF, continuing to build global momentum for CASGEVY, and advancing the launch of JOURNAVX in acute pain.”
— Reshma Kewalramani, Q3 2025 Earnings Press Release
VRTX Earnings Trends
VRTX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
VRTX EPS Trend
Earnings per share: estimate vs actual
VRTX Revenue Trend
Quarterly revenue: estimate vs actual
VRTX Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $4.31 | $4.47 | +3.81% | $2.99B | -0.36% |
| Q4 25 MISS FY | $5.15 | $5.03 | -2.30% | $3.19B | +0.48% |
| FY Full Year | — | $18.40 | — | $12.00B | — |
| Q3 25 BEAT | $4.58 | $4.80 | +4.87% | $3.08B | +0.56% |
| Q2 25 BEAT | $4.25 | $4.52 | +6.33% | $2.96B | +2.00% |
| Q1 25 MISS | $4.29 | $4.06 | -5.44% | $2.77B | -3.17% |